Full Press Release Details
Inspira Expands U.S. Commercial Footprint: Deploys
ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State
Ra'anana, Israel, February 17, 2026 - Inspira Technologies
OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira Technologies" or the "Company"), a pioneer in innovative life-support
and diagnostic technologies, today announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and
Drug Administration ("FDA")-cleared INSPIRA ART100 system (the "ART100") at a new and additional leading
U.S. academic medical center.
The partnering institution is a prominent health system serving a large
patient population, and is ranked among New York State's top 10 hospitals in Newsweek's World's Best Hospitals 2025
This deployment expands Inspira Technologies' presence within
the Tier-1 U.S. hospital market. The ART100 system has been integrated into the center's clinical workflow to support a structured
evaluation designed to define clinical protocols and potential broader institutional adoption. This activity builds upon the Company's
FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities.
Mike Hershkovitz, Global VP Sales at Inspira Technologies, commented:
"This deployment represents a continued execution of our U.S. commercial strategy. Following our recent interaction with other leading
healthcare providers, entering another leading institution in New York State demonstrates that the ART100 meets the operational and clinical
demands of top-tier U.S. healthcare providers. Our focus remains on converting these high-profile evaluations into a sustainable commercial
pipeline and further expanding our footprint across key U.S. markets."
About Inspira Technologies
Inspira Technologies is a commercial-stage
medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's FDA-cleared
INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures
outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation
while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA , a proprietary blood sensor
platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining
of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape.
For more information, visit: https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express
or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current
expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements
when it discusses that this evaluation builds upon the Company's FDA clearance and ongoing commercial activity at other leading
U.S. healthcare facilities, its U.S. commercial strategy, benefits and advantages of ART100 and conversion of high-profile evaluations
into a sustainable commercial pipeline and further expansion of its footprint across key U.S. markets . These forward-looking statements
and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except
as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual
report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website at www.sec.gov.
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485